Del Carmen of Catalyst Pharma sells $256k in shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Catalyst Pharmaceuticals Inc (CPRX)
Catalyst Pharmaceuticals Inc stock price live, this page displays NASDAQ CPRX stock exchange data. View the CPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Catalyst Pharmaceuticals Inc real time stock price chart below.
What Is the Catalyst Pharmaceuticals Inc Stock Price Today?
The Catalyst Pharmaceuticals Inc stock price today is 24.130.
What Is the Stock Symbol for Catalyst Pharmaceuticals Inc?
The stock symbol for Catalyst Pharmaceuticals Inc is "CPRX."
What Stock Exchange Does Catalyst Pharmaceuticals Inc Trade On?
Catalyst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Catalyst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Catalyst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CPRX quote. (ISIN: US14888U1016)
What Is the Catalyst Pharmaceuticals Inc Stock Price Today?
The Catalyst Pharmaceuticals Inc stock price today is 24.130.
What Is the Stock Symbol for Catalyst Pharmaceuticals Inc?
The stock symbol for Catalyst Pharmaceuticals Inc is "CPRX."
What Stock Exchange Does Catalyst Pharmaceuticals Inc Trade On?
Catalyst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Catalyst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Catalyst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CPRX quote. (ISIN: US14888U1016)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.260
24.150
52 wk Range
19.050
26.580
CPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.26024.150
52 wk Range
19.05026.580
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CPRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
34.857
Upside
+44.46%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Form 144 CATALYST PHARMACEUTICALS For: 26 November
- Investing.com
- Del Carmen of Catalyst Pharma sells $256k in shares
- Investing.com
- Form 144 CATALYST PHARMACEUTICALS For: 26 November
- Investing.com
- Form 144 CATALYST PHARMACEUTICALS For: 12 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Catalyst Pharmaceuticals Inc Company Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Catalyst Pharmaceuticals reported Q3 2025 EPS of $0.68 (106.06% above forecast) and revenue of $148.4 million (8.82% above expectations), with stock rising 4.35% in premarket trading.
- Total revenue increased 15.3% YoY, driven by strong performance of Firdapse ($92.2M, +16.2%) and AGAMREE ($32.4M, +115.2%), despite FYCOMPA decline (-25.8%).
- The company raised its 2025 revenue guidance to $565-$585 million, with Firdapse expected to contribute $355-$360M, AGAMREE $105-$115M, and FYCOMPA $100-$110M.
- Net income reached $52.8 million ($0.42 per diluted share), up 20.3% YoY, with a robust cash position of $689.9 million and no debt.
- CEO Richard Daly highlighted 'strong momentum' while management addressed strategies to counter generic competition for FYCOMPA and expand AGAMREE into other disorders.
Last Updated: 2025-11-06, 10:52 a/m
Read Full TranscriptCompare CPRX to Peers and Sector
Metrics to compare | CPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.6x | 2.8x | −0.6x | |
PEG Ratio | 0.29 | 0.12 | 0.00 | |
Price/Book | 3.2x | 6.8x | 2.6x | |
Price / LTM Sales | 5.1x | 9.0x | 3.4x | |
Upside (Analyst Target) | 49.7% | 151.9% | 42.0% | |
Fair Value Upside | Unlock | 11.0% | 5.8% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.857
(+44.46% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
0.68 / 0.33
Revenue / Forecast
148.40M / 136.37M
People Also Watch
FAQ
What Is the Catalyst Pharmaceuticals (CPRX) Stock Price Today?
The Catalyst Pharmaceuticals stock price today is 24.130
What Stock Exchange Does Catalyst Pharmaceuticals Trade On?
Catalyst Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Catalyst Pharmaceuticals?
The stock symbol for Catalyst Pharmaceuticals is "CPRX."
What Is the Catalyst Pharmaceuticals Market Cap?
As of today, Catalyst Pharmaceuticals market cap is 2.96B.
What Is Catalyst Pharmaceuticals's Earnings Per Share (TTM)?
The Catalyst Pharmaceuticals EPS (TTM) is 1.71.
When Is the Next Catalyst Pharmaceuticals Earnings Date?
Catalyst Pharmaceuticals will release its next earnings report on Mar 18, 2026.
From a Technical Analysis Perspective, Is CPRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Catalyst Pharmaceuticals Stock Split?
Catalyst Pharmaceuticals has split 0 times.
How Many Employees Does Catalyst Pharmaceuticals Have?
Catalyst Pharmaceuticals has 181 employees.
What is the current trading status of Catalyst Pharmaceuticals (CPRX)?
As of Jan 22, 2026, Catalyst Pharmaceuticals (CPRX) is trading at a price of 24.130, with a previous close of 23.380. The stock has fluctuated within a day range of 23.260 to 24.150, while its 52-week range spans from 19.050 to 26.580.
What Is Catalyst Pharmaceuticals (CPRX) Price Target According to Analysts?
The average 12-month price target for Catalyst Pharmaceuticals is USD34.857, with a high estimate of USD40 and a low estimate of USD32. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.46% Upside potential.
What Is the CPRX Premarket Price?
CPRX's last pre-market stock price is 23.350. The pre-market share volume is 470.000, and the stock has decreased by -0.030, or -0.130%.
What Is the CPRX After Hours Price?
CPRX's last after hours stock price is 23.925, the stock has decreased by -0.205, or -0.850%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.